ADARx Pharmaceuticals, Inc.（ADRX）财务数据ADRXADARx Pharmaceuticals, Inc.

Evaluating the bottom line, ADARx Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4006.84%, while the net margin is -3452.95%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ADRX converts its operational activities into shareholder value.

In the context of the broader market, ADRX competes directly with industry leaders such as NUVB and TYRA. With a market capitalization of $1.52B, it holds a leading position in the sector. When comparing efficiency, ADRX's gross margin of N/A stands against NUVB's 78.17% and TYRA's N/A. Such benchmarking helps identify whether ADARx Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown poor financial performance, with total revenue of only $2,140,000 in Q1 2026 and a net margin of -3,452.95% in Q2 2026, reflecting significant losses.